CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop proprietary targeted medicines primarily for cancer treatment, today announced a presentation at CHI’s Discovery on Target: Developing Inhibitors for Promising Drug Targets, which is being held at the World Trade Center in Boston, Massachusetts from October 15-18, 2007. On October 16, 2007, Curis scientists presented a poster entitled “Potent Anti-Cancer Activity In Vitro and In Vivo by a Novel, Small Molecule Inhibitor of HDAC, EGFR and Her2” during a Poster Session. This presentation included in vivo efficacy and pharmacodynamic preclinical study results of CUDC-101, Curis’ proprietary small molecule drug candidate. CUDC-101 is an HDAC, EGFR and Her2 inhibitor, which displays potency improvements over FDA-approved EGFR and EGFR/Her2 inhibitors as well as over a FDA-approved HDAC inhibitor in multiple cell lines across several cancer types including lung, breast, prostate, colon, liver, pancreas and others. Curis believes that CUDC-101 is the first single agent under development to simultaneously inhibit HDAC, EGFR and Her2, three clinically validated cancer targets.
